Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Deferasirox
Drug ID BADD_D00594
Description Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Indications and Usage For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
Marketing Status approved; investigational
ATC Code V03AC03
DrugBank ID DB01609
KEGG ID D03669
MeSH ID D000077588
PubChem ID 214348
TTD Drug ID D0Q5UQ
NDC Product Code 49706-2103; 59285-010; 66039-871; 31722-030; 43598-852; 45963-454; 45963-456; 67877-552; 69238-1703; 69452-161; 69539-200; 70700-271; 70771-1410; 70771-1471; 58032-2017; 0078-0468; 0078-0469; 31722-013; 43598-854; 69238-1488; 69452-159; 69539-023; 46708-410; 57664-768; 62332-324; 62756-568; 69539-021; 69539-073; 69539-199; 62332-412; 67877-550; 67877-553; 69097-391; 69097-560; 69539-022; 70771-1472; 65727-037; 0078-0655; 42806-371; 43598-851; 67877-554; 68462-495; 68462-496; 69097-392; 70710-1012; 62512-0078; 0078-0470; 0078-0654; 0078-0720; 31722-029; 43598-856; 46708-411; 46708-412; 69097-393; 69238-1486; 69539-303; 70710-1276; 72205-176; 14501-0049; 63278-1070; 65085-0063; 66022-0301; 0078-0656; 31722-031; 43598-855; 57664-769; 62332-325; 62756-569; 69539-075; 70710-1011; 72205-075; 72647-372; 74436-0323; 31722-012; 43598-853; 62332-326; 62332-411; 62756-570; 68462-494; 69097-570; 69238-1487; 69238-1702; 69238-1704; 70710-1013; 70771-1411; 70771-1473; 0591-3853; 72647-371; 0591-2961; 11722-040; 53104-7713; 59651-419; 0078-0727; 42806-372; 46708-324; 46708-325; 57664-770; 67877-549; 69539-074; 70700-270; 72205-076; 65015-738; 0078-0713; 31722-011; 42806-373; 45963-455; 46708-326; 62332-410; 67877-551; 69097-550; 69452-160; 70700-269; 70710-1275; 70710-1277; 70771-1409; 72647-373; 65372-1164
UNII V8G4MOF2V9
Synonyms Deferasirox | 4-(3,5-Bis-(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl)benzoic acid | ICL 670A | ICL-670A | ICL670A | ICL-670 | ICL670 | ICL 670 | Exjade
Chemical Information
Molecular Formula C21H15N3O4
CAS Registry Number 201530-41-8
SMILES C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Spinal disorder15.02.04.0230.001859%-
Decreased appetite08.01.09.028; 14.03.01.0050.048202%
Renal injury12.01.05.001; 20.01.03.0150.008550%-
Inner ear disorder04.04.02.002---
Ulcer haemorrhage08.03.06.003; 24.07.01.0400.001859%-
Blood disorder01.05.01.0040.010161%-
Immunodeficiency10.03.02.0020.004337%-
Bone marrow disorder01.05.01.0060.007063%-
Disease progression08.01.03.0380.060717%
Disease recurrence08.01.03.0500.004337%-
Drug intolerance08.06.01.0130.054645%-
Hepatic lesion09.01.08.0050.001239%-
Hepatobiliary disease09.01.08.003---
Pigmentation disorder23.05.03.001---
Venoocclusive disease24.03.02.0160.001239%-
Metabolic encephalopathy14.11.01.013; 17.13.01.0010.002478%-
Urinary tract pain20.02.03.0130.003346%
Renal impairment20.01.03.0100.065054%-
Respiratory tract infection11.01.08.017; 22.07.07.001---
Poor quality sleep17.15.04.002; 19.02.05.0050.003965%-
Middle ear effusion04.05.03.0010.001239%-
Bowel movement irregularity07.02.03.0030.001239%-
Hypophagia07.01.06.010; 14.03.01.006; 19.09.01.0040.003717%-
Skin haemorrhage23.06.07.001; 24.07.01.1030.002726%-
Osteonecrosis of jaw15.02.04.010; 24.04.05.005--
Chronic kidney disease20.01.03.0170.007435%
Bone marrow failure01.03.03.0050.009913%
Loose tooth07.09.05.0090.003965%-
Iron overload12.02.08.005; 14.13.03.0020.027756%
Cytopenia01.03.03.0120.002478%-
The 15th Page    First    Pre   15 16 17 18    Next   Last    Total 18 Pages